{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:28:42Z","timestamp":1790717322788,"version":"4.1.0"},"reference-count":113,"publisher":"Informa UK Limited","issue":"1","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Neurodegener. Dis. Manag."],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.2217\/nmt-2018-0033","type":"journal-article","created":{"date-parts":[[2018,11,27]],"date-time":"2018-11-27T10:44:25Z","timestamp":1543315465000},"page":"5-23","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":253,"title":["Patisiran, an RNAi Therapeutic for the Treatment of Hereditary Transthyretin-Mediated Amyloidosis"],"prefix":"10.1080","volume":"9","author":[{"given":"Arnt V","family":"Kristen","sequence":"first","affiliation":[{"name":"Department of Cardiology University of Heidelberg\rHeidelberg\rD-69120\rGermany"},{"name":"Cardiovascular Center Darmstadt\rDarmstadt\r64287\rGermany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Senda","family":"Ajroud-Driss","sequence":"additional","affiliation":[{"name":"Department of Neurology Northwestern University Feinberg School of Medicine\rChicago\rIL\r60611\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Concei\u00e7\u00e3o","sequence":"additional","affiliation":[{"name":"Centro Hospitalar Lisboa Norte Hospital de Santa Maria Universidade de Lisboa Faculdade de Medicina\r1649-028\rPortugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Gorevic","sequence":"additional","affiliation":[{"name":"Department of Medicine Mount Sinai Medical Center\rNew York\rNY\r10029\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodoros","family":"Kyriakides","sequence":"additional","affiliation":[{"name":"The Cyprus Institute of Neurology & Genetics\rNicosia\r1683\rCyprus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Obici","sequence":"additional","affiliation":[{"name":"Amyloidosis Research & Treatment Centre Fondazione IRCCS Policlinico San Matteo\rPavia\r27100\rItaly"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2018,11,27]]},"reference":[{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-biochem-061516-045115"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/msj.21352"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1080\/13506129.2016.1257986"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2010.84"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2010.03215.x"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-8-31"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.87.7.2843"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001870"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11897-013-0182-4"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.3109\/07853890.2015.1068949"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0969-2126(97)00215-3"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12265-015-9613-9"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.62.7.1057"},{"key":"e_1_3_2_16_1","unstructured":"Pfizer . Recognizing TTR-FAP: a rare disease with a global presence ( 2014 ). https:\/\/www.recognizingttr-fap.com\/epidemiology ."},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.1320600606"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0000000000000288"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1515\/bmc-2013-0038"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/iub.340"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.7754382"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.RA118.003990"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1802977115"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.3109\/13506129.2012.668501"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2012.754348"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12585"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2012-301924"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.03.596"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/humu.22619"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/humu.1132"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehs123"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI111390"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.078915"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI113966"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-9-61"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/jns.12153"},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.acvd.2013.06.051"},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0000000000000289"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.20644"},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11910-013-0435-3"},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000267338.45673.f4"},{"issue":"1","key":"e_1_3_2_42_1","first-page":"13","article-title":"Analysis of disease progression in patients with transthyretin cardiac amyloidosis","volume":"10","author":"Gillmore JD","year":"2015","unstructured":"Gillmore JD , MaurerMS, VestJet al. Analysis of disease progression in patients with transthyretin cardiac amyloidosis . Orphanet. J. Rare Dis.10 ( Suppl. 1 ), 13 ( 2015 ).","journal-title":"Orphanet. J. Rare Dis."},{"key":"e_1_3_2_43_1","first-page":"88","volume-title":"Amyloid and Amyloidosis","author":"Coutinho P","year":"1980","unstructured":"Coutinho P , DeSilvaA, LimaJ, BarbosaA . Forty years of experience with type I amyloid neuropathy: review of 483 cases . In : Amyloid and Amyloidosis . GlennerG, CostaP, de FreitasA ( Eds ). Excerpta Medica, Amsterdam, The Netherlands, 88 \u2013 98 ( 1980 )."},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2011-301299"},{"key":"e_1_3_2_45_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756285612470192"},{"key":"e_1_3_2_46_1","doi-asserted-by":"publisher","DOI":"10.1002\/clc.4960220604"},{"key":"e_1_3_2_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2012.04.015"},{"key":"e_1_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-014-9462-7"},{"key":"e_1_3_2_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-6196(12)60388-7"},{"key":"e_1_3_2_50_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehr383"},{"key":"e_1_3_2_51_1","doi-asserted-by":"publisher","DOI":"10.3109\/13506129.2015.1019610"},{"key":"e_1_3_2_52_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11897-016-0300-1"},{"key":"e_1_3_2_53_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000000574"},{"key":"e_1_3_2_54_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.TP.0000092307.98347.CB"},{"key":"e_1_3_2_55_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000001021"},{"key":"e_1_3_2_56_1","doi-asserted-by":"publisher","DOI":"10.1080\/13506120903090726"},{"key":"e_1_3_2_57_1","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-10-S1-P19"},{"key":"e_1_3_2_58_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181ea15d4"},{"key":"e_1_3_2_59_1","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2009.390"},{"key":"e_1_3_2_60_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000003001"},{"key":"e_1_3_2_61_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0012.2006.00527.x"},{"key":"e_1_3_2_62_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3675"},{"key":"e_1_3_2_63_1","unstructured":"European Medicines Agency . Summary of product characteristics: Vyndaqel 2018 . http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002294\/WC500117862.pdf ."},{"key":"e_1_3_2_64_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182661eb1"},{"key":"e_1_3_2_65_1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.12225"},{"key":"e_1_3_2_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2016.01.046"},{"key":"e_1_3_2_67_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-016-8064-9"},{"key":"e_1_3_2_68_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-016-8337-3"},{"key":"e_1_3_2_69_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805689"},{"key":"e_1_3_2_70_1","doi-asserted-by":"publisher","DOI":"10.1080\/13506120600960882"},{"key":"e_1_3_2_71_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.283815"},{"key":"e_1_3_2_72_1","unstructured":"Quarta CC FalkRH SolomonSDet al. The prevalence of cardiac amyloidosis in familial amyloidotic polyneuropathy with predominant neuropathy: the diflunisal trial . XVth International Symposium on Amyloidosis (ISA) Indianapolis IN USA April 27\u2013May 12014 ."},{"key":"e_1_3_2_73_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-7133.2012.00303.x"},{"key":"e_1_3_2_74_1","doi-asserted-by":"crossref","unstructured":"Sekijima Y TojoK MoritaH KoyamaJ YazakiM IkedaS . Safety and efficacy of long-term diflunisal administration in familial amyloid polyneuropathy \u2013 summary of ten years therapeutic experience . Presented at: XVth International Symposium on Amyloidosis (ISA) Indianapolis IN USA 27 April\u20131 May 2014 .","DOI":"10.1212\/WNL.80.7_supplement.PD1.009"},{"key":"e_1_3_2_75_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.160.14.2093"},{"key":"e_1_3_2_76_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001389"},{"key":"e_1_3_2_77_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.2014.856881"},{"key":"e_1_3_2_78_1","unstructured":"European Medicines Agency . Summary of product characteristics: Tegsedi 284mg solution for injection in pre-filled syringe ( 2018 ). www.ema.europa.eu\/documents\/product-information\/tegsedi-epar-product-information_en.pdf ."},{"key":"e_1_3_2_79_1","unstructured":"Akcea Therapeutics Inc . US prescribing information: TEGSEDI\u2122 (inotersen) injection for subcutaneous use ( 2018 ). https:\/\/tegsedi.com\/wp-content\/uploads\/2018\/10\/prescribing-information.pdf ."},{"key":"e_1_3_2_80_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716793"},{"key":"e_1_3_2_81_1","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-8-74"},{"key":"e_1_3_2_82_1","unstructured":"Obici L PerliniS PalladiniGet al. A Phase II study of doxycycline plus tauroursodeoxycholic acid in transthyretin amyloidosis . XIVth International Symposium on Amyloidosis (ISA) Uppsala Sweden ( 2016 ). Poster PA96 ."},{"key":"e_1_3_2_83_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep25080"},{"key":"e_1_3_2_84_1","doi-asserted-by":"publisher","DOI":"10.3109\/13506129.2016.1148025"},{"key":"e_1_3_2_85_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0004.1991.tb03085.x"},{"key":"e_1_3_2_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(17)39100-7"},{"key":"e_1_3_2_87_1","unstructured":"Alnylam Pharmaceuticals . US prescribing information: ONPATTRO (patisiran) lipid complex injection for intravenous use . www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/210922s000lbl.pdf ."},{"key":"e_1_3_2_88_1","unstructured":"European Medicines Agency . Summary of opinion (initial authorisation): Onpattro (patisiran) ( 2018 ). https:\/\/www.ema.europa.eu\/documents\/smop-initial\/chmp-summary-positive-opinion-onpattro_en.pdf ."},{"key":"e_1_3_2_89_1","doi-asserted-by":"publisher","DOI":"10.1080\/13506120701461368"},{"key":"e_1_3_2_90_1","doi-asserted-by":"publisher","DOI":"10.1002\/lt.21395"},{"key":"e_1_3_2_91_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04433.x"},{"key":"e_1_3_2_92_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.7614"},{"key":"e_1_3_2_93_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa070265"},{"key":"e_1_3_2_94_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)05252-1"},{"key":"e_1_3_2_95_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/123.7.1495"},{"key":"e_1_3_2_96_1","doi-asserted-by":"publisher","DOI":"10.1038\/418244a"},{"key":"e_1_3_2_97_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1208760"},{"key":"e_1_3_2_98_1","doi-asserted-by":"publisher","DOI":"10.2174\/1566524043360375"},{"key":"e_1_3_2_99_1","doi-asserted-by":"publisher","DOI":"10.1038\/35078107"},{"issue":"24","key":"e_1_3_2_100_1","first-page":"6774","article-title":"Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma","volume":"52","author":"Huang SK","year":"1992","unstructured":"Huang SK , MayhewE, GilaniS, LasicDD, MartinFJ, PapahadjopoulosD . Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma . Cancer Res.52 ( 24 ), 6774 \u2013 6781 ( 1992 ).","journal-title":"Cancer Res."},{"key":"e_1_3_2_101_1","doi-asserted-by":"publisher","DOI":"10.1089\/nat.2018.0721"},{"key":"e_1_3_2_102_1","doi-asserted-by":"publisher","DOI":"10.1080\/13506129.2016.1272452"},{"key":"e_1_3_2_103_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-015-0326-6"},{"key":"e_1_3_2_104_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716153"},{"issue":"1","key":"e_1_3_2_105_1","first-page":"165","article-title":"Long-term, open-label clinical experience with patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin-mediated (hATTR) amyloidosis with polyneuropathy","volume":"12","author":"Berk J","year":"2017","unstructured":"Berk J , AdamsD, SuhrOet al. Long-term, open-label clinical experience with patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin-mediated (hATTR) amyloidosis with polyneuropathy . Orphanet. J. Rare Dis.12 ( Suppl. 1 ), 165 ( 2017 ).","journal-title":"Orphanet. J. Rare Dis."},{"key":"e_1_3_2_106_1","doi-asserted-by":"crossref","unstructured":"Coelho T SuhrOB ConceicaoIet al. Relationship between TTR knockdown and change in mNIS+7: Preliminary correlation findings from the phase 2 open-label extension study of patisiran an investigational RNAi therapeutic for hereditary ATTR amyloidosis with polyneuropathy . Presented at: XIVth International Symposium On Amyloidosis (ISA) Uppsula Sweden 3\u20137 July 2016 .","DOI":"10.1016\/j.nmd.2016.06.206"},{"key":"e_1_3_2_107_1","doi-asserted-by":"crossref","unstructured":"Adams D CoelhoT ConceicaoIet al. Phase 2 open-label extension (OLE) study of patisiran an investigational RNAi therapeutic for the treatment of polyneuropathy due to hereditary ATTR (hATTR) amyloidosis: Final 24-month data . American Academy of Neurology (AAN) Boston MA USAApril 22\u201328 2017 .","DOI":"10.1212\/WNL.88.16_supplement.S27.004"},{"key":"e_1_3_2_108_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-017-0948-5"},{"key":"e_1_3_2_109_1","doi-asserted-by":"publisher","DOI":"10.1111\/jns5.12059"},{"key":"e_1_3_2_110_1","article-title":"Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis: an analysis of the APOLLO study","author":"Solomon SD","year":"2018","unstructured":"Solomon SD , AdamsD, KristenAet al. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis: an analysis of the APOLLO study . Circulation ( 2018 ) ( In press ).","journal-title":"Circulation"},{"key":"e_1_3_2_111_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.113.006242"},{"key":"e_1_3_2_112_1","unstructured":"Suhr OB Gonzalez-DuarteA O\u2019RiordanWet al. Long-term use of patisiran an investigational RNAi therapeutic in patients with hereditary transthyretin-mediated amyloidosis: baseline demographics and interim data form global open label extension study . Presented at: XVIth International Symposium On Amyloidosis (ISA) Kumamoto Japan . 26\u201329 March 2018 ."},{"issue":"1","key":"e_1_3_2_113_1","first-page":"165","article-title":"Patisiran, an investigational RNAi therapeutic for the treatment of hereditary ATTR amyloidosis with polyneuropathy: results from the Phase 3 APOLLO study","volume":"12","author":"Adams D","year":"2017","unstructured":"Adams D , Gonzalez-DuarteA, O\u2019RiordanWet al. Patisiran, an investigational RNAi therapeutic for the treatment of hereditary ATTR amyloidosis with polyneuropathy: results from the Phase 3 APOLLO study . Orphanet. J. Rare Dis.12 ( Suppl. 1 ), 165 ( 2017 ).","journal-title":"Orphanet. J. Rare Dis."},{"key":"e_1_3_2_114_1","unstructured":"Polydefkis M AdamsD KristenAet al. Infusion Related Reactions in Patients With hATTR Amyloidosis Treated With Patisiran . Peripheral Nerve Society (PNS) Baltimore MD USA ( 2018 )."},{"key":"e_1_3_2_115_1","unstructured":"Taubel J ZimmermannT KarstenVet al. Phase 1 study of ALN-TTRsc02 a subcutaneously administered investigational RNAi therapeutic for the treatment of transthyretin-mediated amyloidosis . Presented at: XVIth International Symposium On Amyloidosis (ISA) Kumamoto Japan26\u201329 March 2018 ."}],"container-title":["Neurodegenerative Disease Management"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/nmt-2018-0033","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T15:48:37Z","timestamp":1716479317000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/nmt-2018-0033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,27]]},"references-count":113,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["10.2217\/nmt-2018-0033"],"URL":"https:\/\/doi.org\/10.2217\/nmt-2018-0033","relation":{},"ISSN":["1758-2024","1758-2032"],"issn-type":[{"value":"1758-2024","type":"print"},{"value":"1758-2032","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,27]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=inmt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=inmt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2018-08-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-10-25","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-11-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}